| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA591: Letermovir for preventing cytomegalovirus disease after a stem cell transplant |
|
Medicine details |
|
| Medicine name | letermovir (Prevymis®) |
| Formulation | 240 mg & 480 mg concentrate for solution for infusion, 240 mg & 480 mg film-coated tablet |
| Reference number | 1441 |
| Indication | Prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT) |
| Company | Merck Sharp & Dohme Ltd |
| BNF chapter | Infections |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/02/2017 |
| NICE guidance | TA591: Letermovir for preventing cytomegalovirus disease after a stem cell transplant |